{"transactions":[{"id":672943,"issuer":{"id":7054,"kind":"organization","name":"BioStem Technologies, Inc.","symbol":"BSEM"},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-08-28T16:15:05.000Z","date":"2026-08-27","kind":"exercise","planned":false,"acquired":false,"shares":7671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units vested on August 27, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These restricted stock units vested on August 27, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7671},"source":{"system":"sec-edgar","filing":"0001441461-26-000005","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658678/000144146126000005/ownership.xml","form_type":"4"}},{"id":672942,"issuer":{"id":7054,"kind":"organization","name":"BioStem Technologies, Inc.","symbol":"BSEM"},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-28T16:15:05.000Z","date":"2026-08-27","kind":"exercise","planned":false,"acquired":true,"shares":7671,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7671,"source":{"system":"sec-edgar","filing":"0001441461-26-000005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658678/000144146126000005/ownership.xml","form_type":"4"}},{"id":746071,"issuer":{"id":7947,"kind":"organization","name":"MetaVia Inc.","symbol":"MTVA"},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T22:29:06.000Z","date":"2026-06-08","kind":"grant","planned":false,"acquired":true,"shares":17186,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units issued to the Reporting Person under the Issuer's Amended and Restated 2022 Equity Incentive Plan, which vests on the earlier of June 8, 2027 or the day immediately prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total number of securities beneficially owned has been adjusted to reflect the Issuer's completion of a 1-for-11 reverse stock split on December 4, 2025."}],"balance_after":20629,"source":{"system":"sec-edgar","filing":"0001104659-26-071469","document":"tm2617186-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1441461/000110465926071469/tm2617186-1_4seq1.xml","form_type":"4"}},{"id":1097760,"issuer":{"id":7947,"kind":"organization","name":"MetaVia Inc.","symbol":"MTVA"},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-01T20:03:19.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":28147,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units issued to the Reporting Person under the Issuer's Amended and Restated 2022 Equity Incentive Plan, which vests on the earlier of June 30, 2026 or the day immediately prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date."}],"balance_after":37887,"source":{"system":"sec-edgar","filing":"0001104659-25-064716","document":"tm2519510-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1441461/000110465925064716/tm2519510-6_4seq1.xml","form_type":"4"}},{"id":1486630,"issuer":{"id":7947,"kind":"organization","name":"MetaVia Inc.","symbol":"MTVA"},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T23:25:09.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":5051,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units issued to the Reporting Person under the Issuer's 2022 Equity Incentive Plan, which vests on the earlier of June 7, 2025 or the day immediately prior to the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total number of securities beneficially owned has been adjusted to reflect the Issuer's completion of a 1-for-8 reverse stock split on December 20, 2023."}],"balance_after":9740,"source":{"system":"sec-edgar","filing":"0001104659-24-069785","document":"tm2416741-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1441461/000110465924069785/tm2416741-3_4seq1.xml","form_type":"4"}},{"id":1821436,"issuer":{"id":7947,"kind":"organization","name":"MetaVia Inc.","symbol":"MTVA"},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-28T10:11:20.000Z","date":"2023-07-27","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F3","text":"Vests on the earlier of July 27, 2024 or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continuing service."}],"balance_after":37500,"source":{"system":"sec-edgar","filing":"0001104659-23-084974","document":"tm2321997-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1441461/000110465923084974/tm2321997-3_4seq1.xml","form_type":"4"}},{"id":1821435,"issuer":{"id":7947,"kind":"organization","name":"MetaVia Inc.","symbol":"MTVA"},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-28T10:11:20.000Z","date":"2023-07-27","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"50% of the RSUs vested immediately, and the remainder will vest in two equal installments on each subsequent anniversary of the date of grant, subject to continuing service."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001104659-23-084974","document":"tm2321997-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1441461/000110465923084974/tm2321997-3_4seq1.xml","form_type":"4"}},{"id":2091808,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2022-12-10T00:38:08.000Z","date":"2022-12-06","kind":"exercise","acquired":false,"shares":1734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 1,734 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer."}],"balance_after":3466,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1734},"source":{"system":"sec-edgar","filing":"0001209191-22-060586","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060586/doc4.xml","form_type":"4"}},{"id":2091807,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-10T00:38:08.000Z","date":"2022-12-06","kind":"sale","acquired":false,"shares":440,"price":4.9215,"value":2165.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations"}],"balance_after":1294,"source":{"system":"sec-edgar","filing":"0001209191-22-060586","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060586/doc4.xml","form_type":"4"}},{"id":2091806,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-10T00:38:08.000Z","date":"2022-12-06","kind":"exercise","acquired":true,"shares":1734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 1,734 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":1734,"source":{"system":"sec-edgar","filing":"0001209191-22-060586","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060586/doc4.xml","form_type":"4"}},{"id":2313733,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Performance Stock Units","published_at":"2022-03-31T21:15:33.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The performance stock units (\"PSUs\") vest on April 5, 2025 based the total shareholder return (\"TSR\") of the issuer over the period from April 1, 2022 to March 31, 2025 and are subject to the continuous service of the reporting person with the issuer. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs, depending on the TSR milestone achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The performance stock units (\"PSUs\") vest on April 5, 2025 based the total shareholder return (\"TSR\") of the issuer over the period from April 1, 2022 to March 31, 2025 and are subject to the continuous service of the reporting person with the issuer. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs, depending on the TSR milestone achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The performance stock units (\"PSUs\") vest on April 5, 2025 based the total shareholder return (\"TSR\") of the issuer over the period from April 1, 2022 to March 31, 2025 and are subject to the continuous service of the reporting person with the issuer. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs, depending on the TSR milestone achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":260000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001209191-22-021793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122021793/doc4.xml","form_type":"4"}},{"id":2317378,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-28T11:00:25.000Z","date":"2022-03-23","kind":"grant","acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."}],"balance_after":260000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001209191-22-021212","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122021212/doc4.xml","form_type":"4"}},{"id":2542143,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2021-10-15T21:20:32.000Z","date":"2021-10-15","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on October 15, 2024, subject to the continued service of the reporting person with the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on October 15, 2024, subject to the continued service of the reporting person with the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on October 15, 2024, subject to the continued service of the reporting person with the issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on October 15, 2024, subject to the continued service of the reporting person with the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on October 15, 2024, subject to the continued service of the reporting person with the issuer."}],"balance_after":400000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001209191-21-060610","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919121060610/doc4.xml","form_type":"4"}},{"id":2542142,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2021-10-15T21:20:32.000Z","date":"2021-10-15","kind":"grant","acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer."}],"balance_after":260000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001209191-21-060610","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919121060610/doc4.xml","form_type":"4"}},{"id":2542141,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Performance Stock Units","published_at":"2021-10-15T21:20:32.000Z","date":"2021-10-15","kind":"grant","acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. No PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. No PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. No PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. No PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. No PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":260000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001209191-21-060610","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919121060610/doc4.xml","form_type":"4"}},{"id":3322755,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy","published_at":"2020-01-03T21:27:43.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":26625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The award will vest over a four (4) year period in equal quarterly installments, the first of which will be on April 2, 2020."}],"balance_after":26625,"derivative":{"exercise_price":61.34,"expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":26625},"source":{"system":"sec-edgar","filing":"0001179110-20-000171","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1441461/000117911020000171/edgar.xml","form_type":"4"}},{"id":3322754,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-01-03T21:27:43.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":5925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The award will vest over a four (4) year period in equal quarterly installments, the first of which will be on April 2, 2020."}],"balance_after":25925,"source":{"system":"sec-edgar","filing":"0001179110-20-000171","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1441461/000117911020000171/edgar.xml","form_type":"4"}},{"id":3986355,"issuer":{"id":165961,"kind":"organization","name":"Aralez Pharmaceuticals Inc.","symbol":"ARLZ"},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares, without par value","published_at":"2018-03-21T21:15:49.000Z","date":"2018-03-19","kind":"sale","acquired":false,"shares":5725,"price":1.7,"value":9732.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This represents shares sold by the issuer on behalf of the reporting person pursuant to an instruction made in accordance with Rule 10b5-1 for payment of withholding tax liability incurred upon the vesting of 15,184 restricted stock units, which were previously granted on March 17, 2016 and which vested on March 17, 2018."}],"balance_after":250188,"source":{"system":"sec-edgar","filing":"0001104659-18-019362","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1441461/000110465918019362/a4.xml","form_type":"4"}},{"id":4322614,"issuer":{"id":165961,"kind":"organization","name":"Aralez Pharmaceuticals Inc.","symbol":"ARLZ"},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-05-13T01:52:57.000Z","date":"2017-05-11","kind":"grant","acquired":true,"shares":92621,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests as to 25% of the shares on May 11, 2018, and the remainder vests in substantially equal installments over the 36 months immediately following such date, subject to continued employment or service to the Company."}],"balance_after":92621,"derivative":{"exercise_price":1.56,"expiration_date":"2027-05-11","underlying":"Common Shares, without par value","underlying_shares":92621},"source":{"system":"sec-edgar","filing":"0001104659-17-032415","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1441461/000110465917032415/a4.xml","form_type":"4"}},{"id":4322613,"issuer":{"id":165961,"kind":"organization","name":"Aralez Pharmaceuticals Inc.","symbol":"ARLZ"},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares, without par value","published_at":"2017-05-13T01:52:57.000Z","date":"2017-05-11","kind":"grant","acquired":true,"shares":80163,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted Stock Units granted pursuant to the Aralez Pharmaceuticals Inc. 2016 Amended and Restated Long-Term Incentive Plan, which vest in substantially equal annual installments over the three years immediately following the date of grant, subject to continued employment or service to the Company."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 58,380 shares of Common Stock and 197,533 Restricted Stock Units."}],"balance_after":255913,"source":{"system":"sec-edgar","filing":"0001104659-17-032415","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1441461/000110465917032415/a4.xml","form_type":"4"}}]}